Theranostics
ISSN: 1838-7640
Global reach, higher impact
Theranostics 2023; 13(4):1287-1288. doi:10.7150/thno.82636 This issue Cite
Erratum
Transcriptional Downregulation of miR-4306 serves as a New Therapeutic Target for Triple Negative Breast Cancer: Erratum
Zitong Zhao1, Lin Li4, Peina Du4, Liying Ma1, Weimin Zhang6, Leilei Zheng1, Bo Lan3, Bailin Zhang5, Fei Ma3, Bo Xu2, Qimin Zhan1,6 
, Yongmei Song1
1. State Key Laboratory of Molecular Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China
2. Breast Cancer Center and the Key Laboratory of Breast Cancer Prevention and Therapy, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin 300060, China
3. Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China
4. BGI-Shenzhen, Shenzhen, Guangdong 518083, China
5. Department of Breast Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China
6. Laboratory of Molecular Oncology, Peking University Cancer Hospital, Beijing 100142, China
Published 2023-2-9
Citation:
Zhao Z, Li L, Du P, Ma L, Zhang W, Zheng L, Lan B, Zhang B, Ma F, Xu B, Zhan Q, Song Y. Transcriptional Downregulation of miR-4306 serves as a New Therapeutic Target for Triple Negative Breast Cancer: Erratum. Theranostics 2023; 13(4):1287-1288. doi:10.7150/thno.82636. https://www.thno.org/v13p1287.htm
Other stylesCorrected-article in Theranostics, Volume 9, 1401
We recently found that some pictures were mistakenly chosen and placed in Figure 5B, Supplementary Figure 1A and Supplementary Figure 4. The correct pictures are provided below. The revised figures do not alter the conclusions of this article. We apologized deeply for our careless and any inconvenience caused.
Figure 1
Correct image for original Figure 5(B) Transwell results for CAL-51 cells after different treatments.
Figure 2
Correct image for original Supplementary Figure 1A Transwell results for breast cancer cells.
Figure 3
Correct image for original Supplementary Figure 4A Matrigel tube formation assay with different treatments.
Figure 4
Correct image for original Supplementary Figure 4E Matrigel tube formation assay with different treatments.
Author contact
Corresponding authors: Yongmei Song, email: symlh2006com or songymac.cn and Qimin Zhan, email: qiminzhan163.com or zhanqiminedu.cn
Citation styles
APA
Zhao, Z., Li, L., Du, P., Ma, L., Zhang, W., Zheng, L., Lan, B., Zhang, B., Ma, F., Xu, B., Zhan, Q., Song, Y. (2023). Transcriptional Downregulation of miR-4306 serves as a New Therapeutic Target for Triple Negative Breast Cancer: Erratum. Theranostics, 13(4), 1287-1288. https://doi.org/10.7150/thno.82636.
ACS
Zhao, Z.; Li, L.; Du, P.; Ma, L.; Zhang, W.; Zheng, L.; Lan, B.; Zhang, B.; Ma, F.; Xu, B.; Zhan, Q.; Song, Y. Transcriptional Downregulation of miR-4306 serves as a New Therapeutic Target for Triple Negative Breast Cancer: Erratum. Theranostics 2023, 13 (4), 1287-1288. DOI: 10.7150/thno.82636.
NLM
Zhao Z, Li L, Du P, Ma L, Zhang W, Zheng L, Lan B, Zhang B, Ma F, Xu B, Zhan Q, Song Y. Transcriptional Downregulation of miR-4306 serves as a New Therapeutic Target for Triple Negative Breast Cancer: Erratum. Theranostics 2023; 13(4):1287-1288. doi:10.7150/thno.82636. https://www.thno.org/v13p1287.htm
CSE
Zhao Z, Li L, Du P, Ma L, Zhang W, Zheng L, Lan B, Zhang B, Ma F, Xu B, Zhan Q, Song Y. 2023. Transcriptional Downregulation of miR-4306 serves as a New Therapeutic Target for Triple Negative Breast Cancer: Erratum. Theranostics. 13(4):1287-1288.
This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.